Sigma Planning Corp raised its holdings in Celgene Co. (NASDAQ:CELG) by 399.8% in the third quarter, HoldingsChannel.com reports. The firm owned 19,834 shares of the biopharmaceutical company’s stock after purchasing an additional 15,866 shares during the period. Sigma Planning Corp’s holdings in Celgene were worth $2,892,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in CELG. Thompson Davis & CO. Inc. grew its stake in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI grew its stake in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Guidant Wealth Advisors bought a new position in shares of Celgene during the 3rd quarter worth $119,000. Motco grew its stake in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares during the period. Finally, Penserra Capital Management LLC bought a new position in shares of Celgene during the 2nd quarter worth $129,000. Hedge funds and other institutional investors own 79.74% of the company’s stock.

CELG has been the subject of several research reports. Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target for the company in a research note on Friday, October 6th. Royal Bank of Canada reiterated a “buy” rating and set a $173.00 price target on shares of Celgene in a research note on Thursday, October 5th. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a research note on Tuesday, September 26th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a research note on Thursday, September 21st. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 price target on shares of Celgene in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have given a buy rating to the company. Celgene presently has a consensus rating of “Buy” and an average target price of $131.18.

Shares of Celgene Co. (NASDAQ:CELG) opened at $106.00 on Friday. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The firm has a market capitalization of $83,460.00, a PE ratio of 25.00, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $1.58 EPS. equities research analysts forecast that Celgene Co. will post 6.68 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Celgene Co. (CELG) Holdings Lifted by Sigma Planning Corp” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/13/celgene-co-celg-holdings-lifted-by-sigma-planning-corp.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.